H. Lundbeck AS (OCSE:HLUN A) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OCSE:HLUN A H. Lundbeck AS OCSE:HLUN A
80 GF Score
Price kr43.85
GF Value kr38.55
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is H. Lundbeck AS FFO?

FFO (Funds from operations) only applies to REITs.

OCSE:HLUN A
80GF Score
H. Lundbeck AS OCSE:HLUN A
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is H. Lundbeck AS (OCSE:HLUN A) Overvalued in 2026?

Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be overvalued. The current stock price of kr43.85 is trading 13.7% above its estimated GF Value™ of kr38.55. GuruFocus considers H. Lundbeck AS to be Modestly Overvalued.

Key valuation signals for OCSE:HLUN A:

  • FFO:
  • GF Value™: kr38.55 vs. price of kr43.85 (13.7% above fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the OCSE:HLUN A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

H. Lundbeck AS Business Description

Address Ottiliavej 9, Valby, DNK, 2500
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
80GF Score

Get the complete analysis for OCSE:HLUN A

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr43.85
Price
kr38.55
GF Value